BIO Statement Concerning the Recent Ruling Issued by the PTO’s Patent Trial and Appeal Board

"It is disappointing that the PTO’s Patent Trial and Appeal Board (PTAB) failed to properly assess the important issues raised by this motion. This cursory and erroneous ruling reinforces the immediate need for Congress and the PTO leadership to take clear and decisive action to prevent any further misuse and abuse of the Inter Partes Review process by hedge funds, extortionists and other questionable entities seeking to undermine it for their own financial benefit." 

Clinton Campaign Proposal Would Hamper Patient Access To Innovative New Cures and Therapies

“The proposal released today by the Clinton campaign would do irreparable harm to the nation’s health innovation system, significantly hindering the ability of emerging biotechnology companies to develop the new cures and therapies that patients need to live longer, more productive lives...

BIO Issues 2016 BIO International Convention Call for Sessions & Speakers

BIO calls on biopharmaceutical, business development, life sciences and policy experts to submit thought-provoking and timely proposals for sessions and speakers at the 2016 BIO International Convention. BIO 2016 will be held June 6-9, 2016 in San Francisco, California.

BIO Statement on Nomination of Dr. Robert Califf as FDA Commissioner

BIO President and CEO Jim Greenwood released the following statement today commending President Barack Obama for his nomination of Dr. Robert Califf as Commissioner of the Food and Drug Administration (FDA):

U.S. Biotech Crops Alliance letter to the White House on agriculture innovation and trade issues

The U.S. Biotech Crops Alliance greatly appreciates your efforts to elevate the U.S.- China dialogue on agricultural innovation. Your engagement with President Xi Jinping at the 2014 APEC Summit established a strong foundation on which to build a robust, mutually beneficial, long-term dialogue on cooperation as it relates to agricultural innovation, including global food security, climate unpredictability and rural economic growth. In this regard, we ask that practical, trade facilitating measures to ensure increased Chinese access to the products of U.S. agriculture be a priority for your upcoming meeting with President Xi.  

2015 BIO Investor Forum Buzz of BIO Winners Announced

BIO is pleased to announce the winners of the 2015 BIO Investor Forum Buzz of BIO contest, which recognizes highly innovative companies in the biotech sector. The Buzz of BIO at the BIO Investor Forum competition featured 19 nominees pulling in over 3,000 votes. The winners are...

BIO Submits Comments Re: CY 2016 Medicare Physician Fee Schedule Proposed Rule

The Biotechnology Industry Organization (BIO) is pleased to submit comments on the Centers for Medicare and Medicaid Services’ (CMS’s) proposed rule entitled Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 20161 (the “Proposed Rule”).

BIO Announces San Diego to Host the World’s Largest Industrial Biotechnology Conference in 2016

BIO officially announced that the 2016 World Congress on Industrial Biotechnology will be held April 17-20, 2016 in San Diego, California at the San Diego Convention Center. BIO is also announcing the call for papers for the event. Leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors are invited to submit proposals and individual papers beginning September 17, 2015.

Multi-state food and ag organization letter to the White House on agriculture innovation and trade issues

Now more than ever, American agriculture needs your continued engagement with China’s President Xi Jinping on agricultural innovation and trade. The undersigned organizations embrace innovation to continue reliably supplying our valued customers in China and in other markets around the world. Sustainably meeting the challenges of global food security is important not only for China, but for all countries, and requires access to innovation and to markets. For these reasons, we ask you to make securing positive action on pending biotechnology issues a priority when you meet with President Xi in Washington, D.C. later this month. 

Kyle Bass Continues Abuse of Patent Challenge System

The Biotechnology Industry Organization (BIO) today released the following statement regarding the recent IPR challenges filed by hedge fund manager Kyle Bass.